Introduction:

Non-specific intravenous human immunoglobulin (IVIG) is a valuable therapeutic resource in specific pathologies, however, there are pathological conditions for which there is not yet a defined therapeutic strategy and due to similarity or biological plausibility, some prescribers end up using it.

Aim:

To identify the indications for which IVIG has been prescribed in the HUS.

Methodology:

A descriptive observational cross-sectional study was performed with retrospective collection of information between January 1, 2017, and December 31, 2019.

Materials and methods:

180 medical records were reviewed, demographic characterization of the study, clinical and pharmacological population of patients who have been prescribed at least one dose of immunoglobulin. In addition, the indications proposed in the clinical history were compared with the indications approved by regulatory authority (Invima).

Results:

It was determined that the population with the highest predominance to which IVIG was prescribed in the HUS, were women in young adulthood. Likewise, the use of IVIG presented a higher frequency in patients with idiopathic purple thrombocytopenia (ITP), Guillain-Barré Syndrome (GBS), Systemic Lupus Erythematosus (SLE) and neonatal jaundice due to other existing hemolysis specified as main diagnoses. The indications for which there is an Invima approval are nonspecific, which means that there is no defined therapeutic strategy with IVIG and therefore that prescribers for similarity or biological plausibility turn out to be using it, for uses not indicated in the sanitary registry (UNIRS), which represented 71 % of indications for which IVIG was prescribed in HUS.

Conclusion:

The indications for the most prescription with IVIG were idiopathic purple thrombocytopenia (ITP) and Guillain-Barré syndrome (GBS). The non-prescribed use of IVIG in this study reached a figure of 71%.